公开(公告)号：US20070049612A1

公开(公告)日：2007-03-01

申请号：US11465726

申请日：2006-08-18

Applicant: Simeon Bowers ,  Albert Garofalo ,  Roy Hom ,  Andrei Konradi ,  Matthew Mattson ,  Martin Neitzel ,  Christopher Semko ,  Anh Truong ,  Jing Wu ,  Ying-zi Xu

Inventor： Simeon Bowers ,  Albert Garofalo ,  Roy Hom ,  Andrei Konradi ,  Matthew Mattson ,  Martin Neitzel ,  Christopher Semko ,  Anh Truong ,  Jing Wu ,  Ying-zi Xu

IPC: A61K31/4745 ,  A61K31/46 ,  C07D451/02

CPC classification number: C07D451/14 ,  C07D471/08 ,  C07D471/18 ,  C07D471/22 ,  C07D498/08

Abstract: The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.

Abstract translation: 本发明提供N-环磺酰氨基化合物和式I的盐：其中A如说明书中所述，R 1和R 2 2结合形成[3.3.1 ]或[3.2.1]环体系，其中氮连接到两个桥头堡碳上，并且[3.3.1]或[3.2.1]环体系任选地与杂芳基或杂环烷基环稠合。 式I的化合物可用于治疗或预防认知障碍，例如阿尔茨海默病。 本发明还包括含有式I化合物的药物组合物，治疗认知障碍的方法，例如阿尔茨海默氏病，以及可用于制备式I化合物的中间体。

公开(公告)号：US20060009493A1

公开(公告)日：2006-01-12

申请号：US10875508

申请日：2004-06-25

Applicant: Marcel Koenig ,  Jingrong Cui ,  Chung Wei ,  Steven Do ,  Fang-Jie Zhang ,  Tomas Vojkovsky ,  John Ramphal ,  Guang Yang ,  Matthew Mattson ,  Christopher Nelson ,  Peng Tang

Inventor： Marcel Koenig ,  Jingrong Cui ,  Chung Wei ,  Steven Do ,  Fang-Jie Zhang ,  Tomas Vojkovsky ,  John Ramphal ,  Guang Yang ,  Matthew Mattson ,  Christopher Nelson ,  Peng Tang

IPC: C07D43/02 ,  A61K31/4439

CPC classification number: C07D209/40 ,  C07D209/34 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D471/04

Abstract: The present invention relates to compounds of the formulae (I)-(XII), wherein R1-R71, A, B, X, Y, G, L and Z are defined herein, and their pharmaceutically acceptable salts. These compounds modulate the activity of c-Met and are therefore expected to be useful in the prevention and treatment of c-Met related disorders such as cancer.

Abstract translation: 本发明涉及式（I） - （XII）的化合物，其中R 1 -R 71，A，B，X，Y，G，L和 Z在本文中定义，及其药学上可接受的盐。 这些化合物调节c-Met的活性，因此预期可用于预防和治疗c-Met相关疾病如癌症。

公开(公告)号：US20050271590A1

公开(公告)日：2005-12-08

申请号：US11124673

申请日：2005-05-09

Applicant: Daniel Schwartz ,  Chang Yu ,  Robert Grubbs ,  Julia Kornfield ,  Scott Fraser ,  Matthew Mattson

Inventor： Daniel Schwartz ,  Chang Yu ,  Robert Grubbs ,  Julia Kornfield ,  Scott Fraser ,  Matthew Mattson

IPC: A61K31/295 ,  A61K31/765 ,  A61K41/00 ,  A61K49/00

CPC classification number: A61K31/135 ,  A61K31/295 ,  A61K31/325 ,  A61K31/37 ,  A61K31/382 ,  A61K31/47 ,  A61K31/495 ,  A61K41/0042 ,  A61K49/0002

Abstract: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment and/or prevention of myopia. An activating energy source is utilized to photopolymerize or crosslink molecules in the sclera, thereby increasing the strength of the tissue. The individual is administered a crosslinking reagent or photopolymerizable molecule that becomes associated with the membrane, which is then precisely exposed to an energy source, such as light or ultrasound.

Abstract translation: 本发明涉及改变眼睛中至少一个组织的至少一部分的物理和/或化学性质。 在具体实施方案中，其涉及治疗和/或预防近视。 活化能源用于光聚合或交联巩膜中的分子，从而增加组织的强度。 给个体施用交联剂或可光聚合的分子，其与膜相关联，然后将其精确地暴露于能量源，例如光或超声波。

公开(公告)号：US20080090817A1

公开(公告)日：2008-04-17

申请号：US11951097

申请日：2007-12-05

Applicant: Simeon Bowers ,  Albert Garofalo ,  Roy Hom ,  Andrei Konradi ,  Matthew Mattson ,  Martin Neitzel ,  Christopher Semko ,  Anh Truong ,  Jing Wu ,  Ying-zi Xu

Inventor： Simeon Bowers ,  Albert Garofalo ,  Roy Hom ,  Andrei Konradi ,  Matthew Mattson ,  Martin Neitzel ,  Christopher Semko ,  Anh Truong ,  Jing Wu ,  Ying-zi Xu

IPC: A61K31/5365 ,  A61K31/437 ,  A61P25/28 ,  C07D497/04 ,  C07D497/14 ,  C07D471/14 ,  A61K31/4985

CPC classification number: C07D451/14 ,  C07D471/08 ,  C07D471/18 ,  C07D471/22 ,  C07D498/08

Abstract: The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.

Abstract translation: 本发明提供N-环磺酰氨基化合物和式I的盐：其中A如说明书中所述，R 1和R 2 2结合形成[3.3.1 ]或[3.2.1]环体系，其中氮连接到两个桥头堡碳上，并且[3.3.1]或[3.2.1]环体系任选地与杂芳基或杂环烷基环稠合。 式I的化合物可用于治疗或预防认知障碍，例如阿尔茨海默病。 本发明还包括含有式I化合物的药物组合物，治疗认知障碍的方法，例如阿尔茨海默氏病，以及可用于制备式I化合物的中间体。

公开(公告)号：US06642232B2

公开(公告)日：2003-11-04

申请号：US10268082

申请日：2002-10-10

Applicant: Matthew Mattson ,  Tomas Vojkovsky ,  Congxin Liang ,  Peng Cho Tang ,  Huiping Guan

Inventor： Matthew Mattson ,  Tomas Vojkovsky ,  Congxin Liang ,  Peng Cho Tang ,  Huiping Guan

IPC: A61K315377

CPC classification number: C07D401/14 ,  C07D403/12 ,  C07D403/14

Abstract: The present invention relates to certain 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives that inhibit kinases, in particular VEGFR and/or PDGFR kinases. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.